Spiracur said today that it raised $16 million debt round from GE Capital for its negative-pressure wound therapy device.
Sunnyvale, Calif.-based Spiracur said it plans to use the proceeds to launch new products, penetrate new care settings and for global expansion.
California device maker Spiracur won reimbursement coverage from insurance giant Health Care Services Corp., covering the SNaP wound care system.
UPDATED July 1, 2014, with comment from KCI.
Kinetic Concepts Inc. said it agreed to pay $280 million to settle a patent infringement lawsuit with Wake Forest University, putting their long-running war over negative-pressure wound therapy to rest.
Kinetic Concepts’ V.A.C. Ulta therapy and Prevena incision management system were awarded Novation’s "Innovative Technology" designation, putting the devices in an elite category within the group purchasing organization’s catalog.
Novation, which represents close to 100,000 healthcare providers, awarded the designations at its annual Innovative Technology Expo, where products were evaluated and reviewed by hospital member-led councils.
Kinetic Concepts Inc. said it won 510(k) clearance from the FDA for a new negative-pressure wound therapy device, the V.A.C.Via, saying it plans to have it on the market in early December.
The V.A.C.Via is a portable wound care system featuring a diaphragm pump for faster draw down, longer battery life and a higher leak rate threshold, according to a press release.
Just weeks after the $485 million merger of Kinetic Concepts and Systagenix, the duo plans to merge forces with LifeCell Corp., forming a 3-headed hydra of wound care, biologics and regenerative therapies.
The new company will be run by KCI president & CEO Joe Woody, with LifeCell commercial operations chief Phil Croxford as senior vice president and "permanent leader" of LifeCell, according to a joint statement.
Kinetic Concepts Inc. said it agreed to acquire 1 of its private wound-care peers, Systagenix, for $485 million.
San Antonio, Texas-based KCI said the deal brings a large suite of complementary advanced wound care products into its portfolio.
Devon Medical today launched its portable extriCARE 2400 Negative Pressure Wound Therapy system at the European Wound Management Association conference is Copenhagen, Denmark, after it won CE Mark approval in the European Union.
"The extriCARE system has proven itself in the U.S. as a powerful device that healthcare professionals can rely on for the management of non-healing wounds, including diabetic ulcers and chronic, acute, traumatic, subacute, and dehisced wounds," Devon Medical founder and CEO Dr. John Bennett said in a press statement.